TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03401892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal vessel diameters and oxygen saturation will be measured with the DVA device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal vessel diameters and oxygen saturation will be measured with the DVA device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT.
Study: NCT01501695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiapride
Description: dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Total duration:8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: mimetic granule: same with 5LGr mimetic tablet: same with tiapride
Study: NCT02006706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000 mg iv Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10 - 25 mg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
Study: NCT01095757

Intervention type: DRUG
Group type: OTHER
Intervention: Plerixafor
Description: 240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is \> 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.
Study: NCT03401892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: Nerve fiber layer thickness and central retinal thickness will be measured using OCT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
Study: NCT04378192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask airway
Description: Insertion of laryngeal mask airway before intubation of a morbidly obese patient
Study: NCT00003118

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical procedure

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00824902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Elastography Imaging
Description: Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
Study: NCT04287231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
Study: NCT04232397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: anlotinib 8mg qd po
Study: NCT04378192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: face mask
Description: use of face mask before intubation of a morbidly obese patient
Study: NCT03381547

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegilodecakin
Description: Pegilodecakin Alone

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegilodecakin
Description: Pegilodecakin Alone

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegilodecakin
Description: Pegilodecakin Alone
Study: NCT00384033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Description: 50 mg tablet, once daily dosing for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Description: 100 mg tablet, once daily dosing for 8 weeks
Study: NCT04287231

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
Study: NCT03789149

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiotherapy
Description: Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.
Study: NCT02993328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN021 Serum
Description: SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAN021 Placebo
Description: SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Study: NCT02600468

Intervention type: DRUG
Intervention: Orencia
Study: NCT00384033

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets and capsules, once daily dosing for 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 60 mg/day
Description: 60 mg capsule, once daily dosing for 8 weeks
Study: NCT03181802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: single injection of 200 International Unit of BoNT-A in 10 bilateral paravertebral intramuscular points for treating chronic LBP
Study: NCT02915679

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample for genetic purpose, psychiatric assessment and pain investigation
Description: All the participant will performed the same evaluation and blood analysis:~* A clinical assessment by psychiatrics assessing psychiatric disorder and suicidal behavior~* Thermal stimulation for pain assessment~* Computer game named Cyberball: test of social exclusion~* Self report questionnaire for the assessment of reject sensitivity, relationship style, impulsivity, childhood trauma.~* Routine blood sampling
Study: NCT02295774

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: standard white light colonoscopy-equivalent to placebo
Description: standard white light colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue MMX tablets
Description: 8x25mg methylene blue MMX tablets administered before a colonoscopy
Study: NCT02051127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate \> 75% of maximum heart rate determined by exercise test before start of the intervention
Study: NCT05186610

Intervention type: PROCEDURE
Intervention: FDG PET/CT guided metabolic core needle biopsy
Description: The target lesion to be biopsied was chosen based on accessibility and the highest metabolic activity (Highest standardized uptake value) on FDG PET/CT imaging. The final needle course was based on the anatomic location of the lesion, FDG avidity, and its relation with vital organs. The procedures were performed under full aseptic precautions and under adequate local anesthesia. The biopsy needle was placed to the target lesion using an automated robotic arm (ARA) workstation (ROBIO-EX, Perfint healthcare Pvt Ltd, Chennai, India).
Study: NCT01464827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets
Study: NCT01068730

Intervention type: DRUG
Group type: OTHER
Intervention: metformin (Diabex)
Description: Tablets, Oral, 500 mg, Once daily, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: metformin (Glucophage™)
Description: Tablets, Oral, 500 mg, Once Daily, single dose
Study: NCT03181802

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
Study: NCT04070625

Intervention type: OTHER
Intervention: Communication book group
Description: Communication book

Intervention type: OTHER
Intervention: Control group
Description: Simple speech therapy
Study: NCT01756352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FET
Description: Radiotracer, surrogate marker for protein synthesis
Study: NCT01888393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumacaftor 200 mg q12h + ivacaftor 250 mg q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumacaftor 200 mg q12h + ivacaftor 250 mg q12h
Study: NCT01086748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally.
Study: NCT04186013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection [Tecentriq]
Description: intravenous infusion of 1.200 mg of Atezolizumab administered intravenously every 3 weeks for a total of 6 doses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy (EBRT)
Description: 60 Gy of radiotherapy in 30 fractions overs 6 weeks at 2 Gy/day
Study: NCT01068730

Intervention type: DRUG
Group type: OTHER
Intervention: metformin (Glucophage™)
Description: Tablets, Oral, 1000 mg, Once daily, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: metformin (Diabex)
Description: Tablets, Oral, 1000 mg, Once daily, single dose
Study: NCT01498211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: 3 mm punch biopsy of the skin at the distal leg.
Study: NCT02313493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby Triple P
Study: NCT01653678

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D-3 (cholecalciferol), 2000 IU

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D-3 (cholecalciferol), 2000 IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Study: NCT02120833

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram® Skin Barrier Emulsion
Description: Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Oatmeal Cream
Description: Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
Study: NCT05007743

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: Frequency of 30 Hz, biphasic, rectangular pulses with a pulse width of 250 µs and an intensity of 20 mA.~Device: Easy Tens+ device (body clock, London, UK)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: Frequency of 30 Hz, biphasic, rectangular pulses with a pulse width of 250 µs and an intensity of 20 mA.~Device: Easy Tens+ device (body clock, London, UK)
Study: NCT01014988

Intervention type: DRUG
Group type: OTHER
Intervention: zanamivir aqueous solution
Description: Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
Study: NCT02460250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
Study: NCT01577953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB010
Description: Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.~Dose levels:~Dose group A: 5 mg hgd40 in 2 mL solution (concentration: 2.5 mg/mL); Dose group B: 10 mg hgd40 in 2 mL solution (concentration: 5.0 mg/mL); Dose group C: 20 mg hgd40 in 2 mL solution (concentration: 10.0 mg/mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.
Study: NCT02101736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: This is an open label Phase II clinical trial. For both cohorts, subjects will receive cabozantinib orally in continuous cycles. Each cycle is 28 days. In absence of progressive disease or dose limiting toxicity (DLT), subjects may continue therapy for a total of 24 cycles. Subjects with radiographic response (20% or greater reduction in tumor volume) at the end of 12 cycles can continue on therapy for up to an additional year. However, for Cohort A, subjects who do not achieve 15% reduction in tumor volume after 8 cycles will be considered treatment failure and taken off study. For Cohort B, the criteria that subjects who do not achieve 15% reduction by 8 cycles are considered treatment failure and taken off study was eliminated. Subjects will be carefully monitored for toxicities associated with cabozantinib.
Study: NCT04235907

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: Internet-guided rehabilitation with weekly phone calls from a physical therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Prescription for physical therapy and a printed list of exercises to complete.
Study: NCT04119895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation and core stabilization exercise
Description: In NMES group, the amplitude of the electrical current will be set at the highest level subject can tolerate.~The lumbar stabilization mode of the device will be used. This mode consists of three phases; warming, contraction and recovery phases. The duration will be set to 35 minutes. In the first 2 minutes (warming phase), frequency is 6 Hz. Contraction phase includes consecutive cycles of contractile frequency of 40 Hz for 6 seconds and the rest frequency of 4 Hz for 12 seconds, lasting a total of 30 minutes. The last 3 minutes (recovery phase) frequency is 3 Hz. The ramp up time is 2 seconds and the ramp down time is 1 second

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham neuromuscular electrical stimulation and core stabilization exercise
Description: In sham NMES group, the amplitude of the electrical current will be set at a minimum level which does not stimulate any contraction.
Study: NCT04406480

Intervention type: GENETIC
Group type: OTHER
Intervention: CGH-array and exome sequencing
Description: A blood sample will be used for CGH-array and exome sequencing
Study: NCT02389257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINIMAG / MEG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINIMAG / ECG
Study: NCT02448940

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Species of Lactobacillus
Description: 2 capsule a day Lactofem probiotics containing Species of Lactobacillus

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: 2 capsule a day containing lactose
Study: NCT02211755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib plus Clofarabine
Description: The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models
Study: NCT04191629

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EO1404

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EO1404

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EO1404

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EO1404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial brushing or Descemet stripping

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial brushing or Descemet stripping
Study: NCT03718689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser etching
Description: Acid etching

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser etching
Description: Acid etching
Study: NCT04176939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine (GSK1437173A)
Description: 2 intramuscular (IM) doses of the HZ/su vaccine administered - first dose at Month 24 and second dose at Month 25.
Study: NCT01958814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
Study: NCT01464827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets
Study: NCT02953847

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactane
Description: 150 mg capsules, Sandoz MCC registration # A/20.2.3/784

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactane
Description: 150 mg capsules, Sandoz MCC registration # A/20.2.3/784
Study: NCT04447430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bright light
Description: treat patients with bright light, 30 min per day, 7 times per week, over 6 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dim red light
Description: treat patients with dim red light, 30 min per day, 7 times per week, over 6 weeks
Study: NCT02249819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Soterix 1x1 anodal tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Soterix 1x1 anodal tDCS
Study: NCT03611244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable seat device devised to maintain lumbar lordosis
Description: The posterior lumbar spine pads are used to maintain lumbar lordosis and fix it with the shoulder strap so that the hip does not slip forward (so that it does not become a sacral sitting posture).~The seat is equipped with a 5 cm air filled villus cushion to relieve pressure on the ischial tuberosity when sitting for a long time. The portable seat device can be moved so that the DMD can sit on the device even when sitting in a wheelchair or a chair for home, school, or outdoors, so that the lumbar lordosis can be constantly maintained.